On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) opened lower -5.13% from the last session, before settling in for the closing price of $1.95. Price fluctuations for AKBA have ranged from $0.80 to $2.48 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 5.16% annually for the last half of the decade. Company’s average yearly earnings per share was noted -1.19% at the time writing. With a float of $207.61 million, this company’s outstanding shares have now reached $211.54 million.
In an organization with 167 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 63.13%, operating margin of -20.45%, and the pretax margin is -27.07%.
Akebia Therapeutics Inc (AKBA) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Akebia Therapeutics Inc is 4.85%, while institutional ownership is 24.83%. The most recent insider transaction that took place on May 13 ’24, was worth 15,140. In this transaction SVP, Chief Legal Officer of this company sold 12,016 shares at a rate of $1.26, taking the stock ownership to the 651,243 shares. Before that another transaction happened on May 13 ’24, when Company’s SVP, Chief Operating Officer sold 34,840 for $1.26, making the entire transaction worth $43,898. This insider now owns 672,092 shares in total.
Akebia Therapeutics Inc (AKBA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1.19% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
Check out the current performance indicators for Akebia Therapeutics Inc (AKBA). In the past quarter, the stock posted a quick ratio of 1.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.25 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.55 million. That was inferior than the volume of 2.99 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 78.72%. Additionally, its Average True Range was 0.09.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 70.91%, which indicates a significant increase from 35.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.94% in the past 14 days, which was lower than the 60.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8429, while its 200-day Moving Average is $1.4619. However, in the short run, Akebia Therapeutics Inc’s stock first resistance to watch stands at $1.9100. Second resistance stands at $1.9700. The third major resistance level sits at $2.0000. If the price goes on to break the first support level at $1.8200, it is likely to go to the next support level at $1.7900. Assuming the price breaks the second support level, the third support level stands at $1.7300.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are currently 218,181K shares outstanding in the company with a market cap of 407.81 million. Presently, the company’s annual sales total 194,620 K according to its annual income of -51,930 K. Last quarter, the company’s sales amounted to 37,430 K and its income totaled -20,040 K.
